The effect of active surveillance for vancomycin-resistant enterococci in high-risk units on vancomycin-resistant enterococci incidence hospital-wide

被引:36
|
作者
Siddiqui, AH
Harris, AD
Hebden, J
Wilson, PD
Morris, JG
Roghmann, MC
机构
[1] VA Maryland Hlth Care Syst, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Div Healthcare Outcomes Res, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA
[4] Univ Maryland, Med Syst, Baltimore, MD 21201 USA
关键词
D O I
10.1067/mic.2002.118616
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. Vancomycin-resistant enterococci (VRE) have become a major cause of nosocomial Infections and are now endemic in many geographic areas, The aim of this study was to describe the effect of active surveillance for patients with VRE in high-risk units on the VRE incidence rate hospital-wide. Methods: We determined 4 time periods based on the intervention of active surveillance: preactive surveillance (period 1), active surveillance (period 2), no active surveillance (period 3), and reinstutition of active surveillance (period 4). VRE incidence rates based on first clinical culture for VRE per 10,000 patient days for each of these periods and incidence rate ratios were then calculated. Results: Active surveillance in high-risk units was associated with a significant reduction in VRE incidence hospital-wide in 2 of the 3 comparisons made. The incidence rate ratio when comparing the first period of active surveillance (period 2) to the preactive surveillance period (period 1) was 0.63 (95 % Cl, 0.38-1.1) it was 0.36 (95 % Cl, 0.23-0.55) when comparing the first period of active surveillance (period 2) to the subsequent period (period 3) and 0.68 (95% Cl, 0.54-0.85) when comparing the second period of active surveillance (period 4) to the prior period without active surveillance periods, Conclusions: Active surveillance culturing for VRE in the high risk-units prevented further VRE transmission, as evidenced by a significant increase in hospital-wide incidence rates when active surveillance was discontinued and a significant decrease in incidence rates when it was restarted.
引用
收藏
页码:40 / 43
页数:4
相关论文
共 50 条
  • [31] Vancomycin-resistant enterococci in Austria
    Allerberger, F
    LassFlorl, C
    Dierich, MP
    Hirschl, AM
    Presterl, E
    Haas, G
    Klare, I
    Witte, W
    WIENER KLINISCHE WOCHENSCHRIFT, 1997, 109 (09) : 312 - 320
  • [32] Commentary: Vancomycin-resistant enterococci
    Welton, L
    Zervos, MJ
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1996, 5 (09) : 535 - 537
  • [33] Topic: Vancomycin-resistant enterococci
    Richard B. Roberts
    Journal of Urban Health, 1998, 75 : 512 - 513
  • [34] Resistance in Vancomycin-Resistant Enterococci
    Miller, William R.
    Murray, Barbara E.
    Rice, Louis B.
    Arias, Cesar A.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2020, 34 (04) : 751 - +
  • [35] The epidemiology of vancomycin-resistant enterococci
    Goossens, H
    CURRENT OPINION IN INFECTIOUS DISEASES, 1999, 12 (06) : 537 - 541
  • [36] Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units
    Perencevich, EN
    Fisman, DN
    Lipsitch, M
    Harris, AD
    Morris, JG
    Smith, DL
    CLINICAL INFECTIOUS DISEASES, 2004, 38 (08) : 1108 - 1115
  • [37] Nitrofurantoin is active against vancomycin-resistant enterococci
    Zhanel, GG
    Hoban, DJ
    Karlowsky, JA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) : 324 - 326
  • [38] Vancomycin-resistant enterococci at Johns Hopkins Hospital
    Gorbach, SL
    Bartlett, JG
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1996, 5 (01) : 1 - 2
  • [39] Vancomycin-resistant enterococci: eradication using vancomycin?
    J Van Prehn
    AM Stemerding
    HK Van Saene
    PE Spronk
    Critical Care, 18 (Suppl 1):
  • [40] VANCOMYCIN PRESCRIBING IN THE ERA OF VANCOMYCIN-RESISTANT ENTEROCOCCI
    POLK, R
    PHARMACOTHERAPY, 1995, 15 (05): : 682 - 683